Home LiteratureArticle Details
PMID: 11244507 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.

Oncogene ·Vol. 20 ·No. 1 ·2001-01-04 ·Pages 88-96

Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H

Abstract

The Smad family proteins are critical components of the transforming growth factor (TGF)-beta signaling pathway. TGF-beta is a multipotent cytokine that elicits many biological functions. In particular, TGF-beta exhibits effects on the cell cycle manifested by G1-phase arrest, differentiation, or apoptosis of several target cells, suggesting that disruption of TGF-beta signaling pathway could be involved in cancer formation. Here we show one missense mutation of the Smad4 gene in the MH1 domain (P102L) and one frame shift mutation resulting in termination in the MH2 domain (Delta(483 - 552)) in acute myelogeneous leukemia. Both of the mutated Smad4 proteins lack transcriptional activities. Concomitant expression of the P102L mutant with wild-type Smad4 inactivates wild-type Smad4 through inhibiting its DNA-binding ability. The Delta(483 - 552) mutant blocks nuclear translocation of wild-type Smad4 and thus disrupts TGF-beta signaling. This is the first report showing that mutations in the Smad4 gene are associated with the pathogenesis of acute myelogeneous leukemia and the obtained results should provide useful insights into the mechanism whereby disruption of TGF-beta signaling pathway could lead to acute myelogeneous leukemia. Oncogene (2001) 20, 88 - 96.

MeSH Terms
Animals COS Cells Cell Division/genetics Cell Transformation, Neoplastic/genetics,metabolism,pathology DNA/metabolism DNA-Binding Proteins/antagonists & inhibitors,biosynthesis,genetics,metabolism,physiology Enzyme Activation/genetics Gene Expression Regulation, Neoplastic Genes, Tumor Suppressor/physiology Genetic Vectors/metabolism Growth Inhibitors/antagonists & inhibitors,physiology HL-60 Cells Humans Jurkat Cells Leukemia, Myeloid, Acute/genetics,metabolism,pathology Mutation Plasminogen Activator Inhibitor 1/metabolism Promoter Regions, Genetic/genetics Protein Binding/genetics Recombinant Fusion Proteins/biosynthesis,genetics,metabolism Serine Proteinase Inhibitors/pharmacology Signal Transduction/genetics Smad3 Protein Smad4 Protein Subcellular Fractions/metabolism Trans-Activators/antagonists & inhibitors,biosynthesis,genetics,metabolism,physiology Transcriptional Activation/genetics Transforming Growth Factor beta/antagonists & inhibitors,physiology Tumor Cells, Cultured
Chemicals
DNA-Binding Proteins Growth Inhibitors Plasminogen Activator Inhibitor 1 Recombinant Fusion Proteins SMAD3 protein, human SMAD4 protein, human Serine Proteinase Inhibitors Smad3 Protein Smad4 Protein Trans-Activators Transforming Growth Factor beta DNA
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Imai Y
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Kurokawa M
Izutsu K
Hangaishi A
Maki K
Ogawa S
Chiba S
Mitani K
Hirai H
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
2001-01-04
Pages
88-96
Language
English
Region
England
NLM ID
8711562
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]